DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dianthus Therapeutics, Inc. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$74.54+2.45 (+3.40%)
Close on Oct 19, 2026
- Market cap
- $4.18B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Dianthus Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Market Cap | $4.17B | $164.85M |
| Enterprise Value | $4.06B | $87.06M |
| PB Ratio | 3.56 | 2.03 |
| P/TBV Ratio | 3.56 | 2.31 |
Income (trailing twelve months)
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$217.84M | -$21.44M |
| Net Income | -$192.25M | -$22.46M |
| EBITDA | -$217.84M | -$16.91M |
| EPS (Diluted) | -$4.15 | -$0.83 |
Returns
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -26.1% | -53.1% |
| Return on Assets (ROA) | -25.0% | -41.0% |
| Return on Invested Capital (ROIC) | -25.4% | -32.0% |
| Return on Capital Employed (ROCE) | -18.5% | -37.8% |
Balance sheet
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $107.61M | $62.42M |
| Net Cash (Debt) | $107.61M | $15.68M |
| Net Cash Per Share | $1.92 | $0.66 |
| Equity (Book Value) | $1.17B | $48.79M |
| Book Value Per Share | $20.95 | $1.36 |
| Tangible Book Value | $1.17B | $23.06M |
| Working Capital | $863.15M | $75.77M |
Financial position
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 26.10 | 3.30 |
| Quick Ratio | 3.13 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$155.38M | -$12.35M |
Efficiency
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.09M | -$703.34K |
| Employee Count | 92 | 74 |
Dividends and yields
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -4.61% | -22.7% |
| Dividend Yield | 0.00% | 1.82% |
| Buyback Yield | -0.01% | -0.73% |
| Shareholder Yield | -0.01% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 55,934,400 | 58,179,650 |
| Shares Change (YoY) | 32.3% | 11.1% |
| Shares Change (QoQ) | 0.39% | 0.54% |
| Float | 50,834,100 | 49,173,100 |
| Shares Held by Insiders | 9.12% | 11.6% |
| Shares Held by Institutions | 118.1% | 59.4% |
Scores
| Measure | Dianthus Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 60.42 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Dianthus Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.